Decrease in serum prolactin levels after long-acting injectable aripiprazole treatment: a case report

Hyperprolactinemia is a severe problem which involves galactorrhea, amenorrhea, sexual dysfunction, and loweredbone mineral density. It can be a long-lasting problem belongs to the atypical antipsychotics that impairs treatmentadherence and quality of life in patients with schizophrenia. The paliperidone palmitate may cause hyperprolactinemiaand there are different approaches in management of this adverse event. Adding oral aripiprazole was shown to beuseful in the treatment of hyperprolactinemia due to paliperidone palmitate. Now the new drug long-acting Injectable(LAI) aripiprazole may become a possible new agent in treatment of schizophrenia patients with paliperidone palmitateinduced hyperprolactinemia.

PDF

___

1. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: Unitary or multiple mechanisms for ‘atypicality’? Clin Neurosci Res. 2003;3(1):108-17. [CrossRef]
2. Fleischhacker WW, Meise U, Gunther V, Kurz M. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl. 1994;382:11-5.
3. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia:a randomized, double-blind, placebo- controlled, dose-response study. Int Clin Psychopharmacol. 2010;25(5):247-56. [CrossRef]
4. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur Neuropsychopharmacol. 2001;11(Suppl.3):S268. [CrossRef]
5. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123-36. [CrossRef]
6. Naono-Nagatomo K, Naono H, Abe H, Takeda R, Funahashi H, Uchimura D, et al. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Asian J Psychiatr. 2017;25:36-41. [CrossRef]
7. Chue P, Chue J. A review of aripiprazole long-acting injection. Curr Med Res Opin. 2016;32(3):441-52. [CrossRef]
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. [CrossRef]
9. Alpak G, Unal A, Bulbul F, Aksoy I, Demir B, Savas HA. Hyperprolactinemia due to paliperidone palmitate and treatment with aripiprazole. Bulletin of Clin Psychopharmacology 2014;24(3):253-6. [CrossRef]
10. Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011;74(2):141-7. [CrossRef]